Multifunctional regulation of angiogenesis by high-density lipoproteins

Cardiovascular Research

Volumn 101, Issue 1, 2014, Pages 145-154

  Prosser, Hamish C G ^a,b   Tan, Joanne T M ^a,b   Dunn, Louise L ^a,b   Patel, Sanjay ^a,b,c   Vanags, Laura Z ^a,b   Bao, Shisan ^b   Ng, Martin K C ^a,b,c   Bursill, Christina A ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Angiogenesis; High density lipoprotein; Inflammation; Ischaemia

Indexed keywords

ANGIOGENIC FACTOR; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIGEL; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTICLE; CELL ASSAY; CELL FUNCTION; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIMB ISCHEMIA; MACROPHAGE; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOGENESIS; HIGH-DENSITY LIPOPROTEIN; INFLAMMATION; ISCHAEMIA;

ANIMALS; APOLIPOPROTEIN A-I; CELLS, CULTURED; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOPROTEINS, HDL; MALE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOM ALLOCATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84891358840     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt234     Document Type: Article

References (49)

1. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 1989;321:1311-1316.
2. Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-1682.
3. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins. Arterioscler Thromb Vasc Biol 2003;23:1724-1731.
4. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA et al. Reconstituted highdensity lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111: 1543-1550.
5. O'Connell BJ, Genest JJ. High-density lipoproteins and endothelial function. Circulation 2001;104:1978-1983.
6. Prosser HC, Ng MK, Bursill CA. The role of cholesterol efflux in mechanisms of endothelial protection by HDL. Curr Opin Lipidol 2012;23:182-189.
7. Barter PJ, Rye KA. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res 2012;53:1755-1766.
8. Lamon BD, Hajjar DP. Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am J Pathol 2008;173:1253-1264.
9. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100:4736-4741.
10. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, MukhamedovaNet al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103:1084-1091.
11. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, YasinM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-2300.
12. Choudhury RP, Rong JX, Trogan E, Elmalem VI, DanskyHM,BreslowJL et al. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol 2004;24:1904-1909.
13. GordonT,CastelliWP, Hjortland MC, KannelWB,Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
14. Nicholls SJ, Cutri B,Worthley SG, Kee P, Rye KA, Bao S et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 2005;25:2416-2421.
15. Rong JX, Li J, Reis ED, Choudhury RP, DanskyHM, Elmalem VI et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001;104:2447-2452.
16. Moulton KS, Heller E, Konerding MA, Flynn E, PalinskiW, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-1732.
17. Sumi M, Sata M, Miura SI, Rye KA, Toya N, Kanaoka Y et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007;27:813-818.
18. Al-Khalili F, Svane B, Janszky I, Ryden L, Orth-Gomer K, Schenck-Gustafsson K. Significant predictors of poor prognosis in women aged ?65 years hospitalized for an acute coronary event. J Intern Med 2002;252:561-569.
19. Berge KE, Canner PL, Hainline AJ. High-density lipoprotein cholesterol and prognosis after myocardial infarction. Circulation 1982;66:1176-1178.
20. Weisweiler P. Isolation and quantitation of apolipoproteins A-I and A-II from human high-density lipoproteins by fast-protein liquid chromatography. Clin Chim Acta 1987; 169:249-254.
21. Bursill CA, Castro ML, Beattie DT, Nakhla S, van der Vorst E, Heather AK et al. Highdensity lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010;30:1773-1778.
22. Hadfield KA, Pattison DI, Brown BE, Hou L, Rye KA, Davies MJ et al. Myeloperoxidasederived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). Biochem J 2013;449:531-542.
23. Limbourg A, Korff T, Napp LC, SchaperW, Drexler H, Limbourg FP. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc 2009;4:1737-1746.
24. Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 2007;10:149-166.
25. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
26. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007;4:491-502.
27. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TNet al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-2061.
28. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009;218:7-29.
29. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-2038.
30. Ibanez B, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A et al. RecombinantHDL( Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 2011;220:72-77.
31. Bhardwaj S, Roy H, Babu M, Shibuya M, Yla-Herttuala S. Adventitial gene transfer of VEGFR-2 specific VEGF-E chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. Atherosclerosis 2011;219:84-91.
32. Donetti E, Baetta R, Comparato C, Altana C, Sartore S, Paoletti R et al. Polymorphonuclear leukocyte-myocyte interaction: an early event in collar-induced rabbit carotid intimal thickening. Exp Cell Res 2002;274:197-206.
33. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 2003;38: 198-203.
34. Miura SI, Fujino M, Matsuo Y, Kawamura A, Tanigawa H, Nishikawa H et al. High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:802-808.
35. Seetharam D, Mineo C, Gormley AK, Gibson LL, VongpatanasinW, Chambliss KL et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 2006;98:63-72.
36. Zhang Q, Yin H, Liu P, Zhang H, She M. Essential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathway. Exp Biol Med (Maywood) 2010;235:1082-1092.
37. Carmeliet P. Manipulating angiogenesis in medicine. J Intern Med 2004;255:538-561.
38. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:E83-E88.
39. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van OosteromAT,De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-580.
40. Mazor R, Alsaigh T, Shaked H, Altshuler AE, Pocock ES, Kistler EB et al. Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells. J Biol Chem 2013;288:598-607.
41. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. Faseb J 1997;11:457-465.
42. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002;160:91-102.
43. Rey S, Semenza GL. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc Res 2010;86:236-242.
44. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22.
45. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996;94:1647-1654.
46. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97:3354-3360.
47. Kee P, Rye KA, Taylor JL, Barrett PH, Barter PJ. Metabolismof apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits. Arterioscler Thromb Vasc Biol 2002;22:1912-1917.
48. BakerPW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999;40:345-353.
49. van der Vorst EP, Vanags LZ,DunnLL, ProsserHC, Rye KA, Bursill CA.High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB J 2013;27:1413-1425.